---
title: "Quality Management Review Template"
methodology: "universal"
complexity: "advanced"
owner: "mirichard"
updated: "2026-09-19"
primary_principles: ["stewardship", "continuous-learning"]
secondary_principles: ["evidence-based-decisions"]
principle_rationale: "Brings quality-system trends, risks and resource needs to management review with recorded decisions and owned improvement actions."
---

# Quality Management Review Template

## When to Use

- When authorized management reviews a pharmaceutical quality system's performance.
- When trends, risks, resource needs, and actions require documented oversight.

## When NOT to Use

- To infer quality effectiveness solely from favorable aggregate indicators.
- Do not report sample values, unsupported ratings, or missing data as verified performance. See [Metric without source](../../../../../docs/principles/anti-patterns.md#metric-source).

## Pairs Well With

- [Capa Management Template](../../../../../domains/delivery/industry-specializations/healthcare-pharmaceutical/compliance/capa_management_template.md).
- [Gxp Training Plan Template](../../../../../domains/delivery/industry-specializations/healthcare-pharmaceutical/compliance/gxp_training_plan_template.md).

Selection context: Delivery domain; universal methodology; advanced complexity. Match the situations above to project phase, risk, team size, and industry using the [decision-engine context model](../../../../../meta/architecture-research/800-801-context-assessment-model.md).

## Completing the worksheet

Replace populated examples with project evidence before circulation. Record the reporting period, baseline, source, owner, and calculation for each measure; define thresholds and approval authority locally. Show unavailable values as unknown rather than zero or a favorable status. Reconcile totals and units, handle zero denominators explicitly, and retain the decision rationale and supporting evidence.


Reference check: [Current source](https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr).


## Applying this template

Treat filled examples, dates, numerical limits, sampling frequencies, and approval outcomes as illustrations. Before execution, replace them with the approved product/site requirements, scientific rationale, method references, responsible reviewer, and acceptance evidence. Record the applicable jurisdiction and current guidance edition; a completed worksheet alone does not demonstrate regulatory compliance.

| Requirement or limit | Applicable source / edition | Product-specific rationale | Approval / date | Execution evidence |
|---|---|---|---|---|
| [Requirement] | [Source] | [Rationale] | [Reviewer / date] | [Record] |


## Document Control

| Document Name | Quality Management Review Template |
| ------------- | ---------------------------------- |
| Document ID   | QMR-TEMP-002                       |
| Version       | 1.0                                |
| Date          | 2025-06-20                         |
| Author        | [Author Name]                      |
| Approved By   | [Quality Head]                     |

### Revision History

| Version | Date       | Changed By | Description of Changes |
| ------- | ---------- | ---------- | ---------------------- |
| 1.0     | 2025-06-20 | [Name]     | Initial release        |

### Approval Matrix

| Role                              | Name          | Signature | Date       |
| --------------------------------- | ------------- | --------- | ---------- |
| Quality Assurance Head            | [Name]        | _________ | __________ |
| Manufacturing/Operations Head     | [Name]        | _________ | __________ |
| Regulatory Affairs Head           | [Name]        | _________ | __________ |
| Site Director/General Manager     | [Name]        | _________ | __________ |
| Quality Management Representative | [Name]        | _________ | __________ |

## Table of Contents

1. [Quality Management System Overview](#quality-management-system-overview)
2. [Review Schedule and Participants](#review-schedule-and-participants)
3. [Review Components](#review-components)
   - [Quality Objectives and KPIs](#quality-objectives-and-kpis)
   - [Process Performance Monitoring](#process-performance-monitoring)
   - [Product Quality Review](#product-quality-review)
   - [Inspection and Audit Findings](#inspection-and-audit-findings)
   - [CAPA Status and Effectiveness](#capa-status-and-effectiveness)
   - [Change Control Review](#change-control-review)
   - [Supplier Quality Assessment](#supplier-quality-assessment)
   - [Training Program Effectiveness](#training-program-effectiveness)
4. [Risk Assessment and Mitigation](#risk-assessment-and-mitigation)
5. [Resource Requirements Review](#resource-requirements-review)
6. [Improvement Initiatives](#improvement-initiatives)
7. [Review Meeting Minutes Template](#review-meeting-minutes-template)
8. [Action Items and Follow-up](#action-items-and-follow-up)
9. [Quality Metrics Dashboard Integration](#quality-metrics-dashboard-integration)
10. [Appendices](#appendices)

## Quality Management System Overview

### Purpose

This Quality Management Review (QMR) template provides a structured framework for evaluating the effectiveness and performance of the pharmaceutical quality system in accordance with ICH Q10, FDA Quality Systems Approach to Pharmaceutical cGMP Regulations, EU GMP Chapter 1, and ISO 13485:2016 (for medical devices). Regular quality management reviews are a regulatory requirement and a critical element of continuous improvement.

### Scope

This review encompasses all GxP-regulated operations, including:
- Manufacturing processes
- Laboratory operations
- Quality systems and procedures
- Regulatory compliance activities
- Supply chain management
- Product lifecycle management

### Regulatory Framework

This quality management review fulfills requirements in:

- **FDA Requirements**:
  - 21 CFR 211.22 - Responsibilities of quality control unit
  - 21 CFR 211.180(e) - Requirements for management review of records and data
  - 21 CFR Part 820 - QMSR (applicable medical-device management review requirements)

- **EU GMP Requirements**:
  - EU GMP Chapter 1 - Pharmaceutical Quality System
  - EU GMP Annex 15 - Qualification and Validation

- **ICH Guidelines**:
  - ICH Q10 - Pharmaceutical Quality System
  - ICH Q9 - Quality Risk Management

- **ISO Standards**:
  - ISO 13485:2016 Section 5.6 - Management Review (for medical devices)
  - ISO 9001:2015 Section 9.3 - Management Review (where applicable)

### Review Periodicity

- Comprehensive reviews: Quarterly
- Annual management review: End of fiscal year
- Ad-hoc reviews: As needed for significant quality events

## Review Schedule and Participants

### Scheduling Guidance

| Review Type | Frequency | Timing | Duration |
|-------------|-----------|--------|----------|
| Executive Quality Review | Quarterly | Within 30 days of quarter end | 2-3 hours |
| Department-Level Reviews | Monthly | Within 15 days of month end | 1-2 hours |
| Annual Management Review | Yearly | Within 60 days of fiscal year end | Full day |

### Required Participants

| Role | Responsibility in Review | Materials to Prepare |
|------|--------------------------|----------------------|
| Quality Management Representative | Facilitate meeting, present quality metrics | Overall quality metrics package, trends analysis |
| Site Head/General Manager | Review resource allocation, strategic direction | Business impact assessment |
| Head of Quality Assurance | Present audit findings, compliance status | Audit metrics, regulatory inspection summary |
| Head of Quality Control | Present laboratory performance metrics | Testing metrics, OOS/OOT trends |
| Head of Manufacturing | Present production quality metrics | Manufacturing performance, deviation trends |
| Head of Engineering/Maintenance | Present facility/equipment status | Facility and equipment metrics |
| Head of Regulatory Affairs | Present regulatory compliance status | Regulatory submission status, commitments tracking |
| Supply Chain Representative | Present supplier quality metrics | Supplier qualification status, performance metrics |

### Optional Participants (Based on Agenda)

- Validation Manager
- IT/Computer Systems Manager
- Training Manager
- R&D Representative
- External Subject Matter Experts

## Review Components

### Quality Objectives and KPIs

#### Strategic Quality Objectives

| Strategic Objective | Target | Current Performance | Trend | Status |
|---------------------|--------|---------------------|-------|--------|
| [Objective 1] | [Target] | [Performance] | [↑/↓/→] | [Met/Not Met] |
| [Objective 2] | [Target] | [Performance] | [↑/↓/→] | [Met/Not Met] |
| [Objective 3] | [Target] | [Performance] | [↑/↓/→] | [Met/Not Met] |

#### Operational Quality KPIs

| KPI Category | Metric | Target | Current Period | Previous Period | Trend | Status |
|--------------|--------|--------|----------------|----------------|-------|--------|
| **Manufacturing** | Right First Time (RFT) | ≥95% | [Value]% | [Value]% | [↑/↓/→] | [Color] |
| | Batch Rejection Rate | ≤1% | [Value]% | [Value]% | [↑/↓/→] | [Color] |
| | Deviation Rate per Batch | ≤1.5 | [Value] | [Value] | [↑/↓/→] | [Color] |
| **Laboratory** | OOS Rate | ≤0.5% | [Value]% | [Value]% | [↑/↓/→] | [Color] |
| | Lab Investigation Cycle Time | ≤15 days | [Value] days | [Value] days | [↑/↓/→] | [Color] |
| | Method Transfer Success Rate | ≥90% | [Value]% | [Value]% | [↑/↓/→] | [Color] |
| **Quality Systems** | CAPA On-Time Closure | ≥90% | [Value]% | [Value]% | [↑/↓/→] | [Color] |
| | Change Control Cycle Time | ≤60 days | [Value] days | [Value] days | [↑/↓/→] | [Color] |
| | Training Compliance | ≥98% | [Value]% | [Value]% | [↑/↓/→] | [Color] |

#### KPI Analysis and Insights

[Provide analysis of key trends, emerging patterns, areas of excellence, and concerns requiring attention. Include root causes for metrics not meeting targets and cross-functional impacts.]

#### Example:

**Manufacturing Quality KPIs**

| KPI | Target | Current Period | Previous Period | Trend | Status |
|-----|--------|----------------|----------------|-------|--------|
| Right First Time (RFT) | ≥95% | 93.2% | 91.8% | ↑ | Yellow |
| Batch Rejection Rate | ≤1% | 0.8% | 1.2% | ↑ | Green |
| Deviation Rate per Batch | ≤1.5 | 1.8 | 2.1 | ↑ | Yellow |

**Analysis:** Manufacturing KPIs show improving trends but RFT remains below target due to ongoing challenges in the sterile filling area. The investigation revealed that 65% of failures were related to environmental monitoring excursions following recent HVAC modifications. An engineering assessment has been completed and corrective actions are in implementation phase. Batch rejection rate has improved significantly due to enhanced pre-review process and operator training program implemented in Q1.

### Process Performance Monitoring

#### Critical Process Parameters (CPP) Review

| Process | CPP | Target Range | % Within Range | Trend | Process Capability (Cpk) |
|---------|-----|--------------|----------------|-------|--------------------------|
| [Process 1] | [Parameter 1] | [Range] | [Value]% | [↑/↓/→] | [Value] |
| | [Parameter 2] | [Range] | [Value]% | [↑/↓/→] | [Value] |
| [Process 2] | [Parameter 1] | [Range] | [Value]% | [↑/↓/→] | [Value] |
| | [Parameter 2] | [Range] | [Value]% | [↑/↓/→] | [Value] |

#### Process Validation Status

| Process | Validation Type | Validation Status | Re-validation Due | Issues Identified |
|---------|----------------|-------------------|-------------------|-------------------|
| [Process 1] | [PV/CPV/Other] | [Status] | [Date] | [Yes/No] |
| [Process 2] | [PV/CPV/Other] | [Status] | [Date] | [Yes/No] |

#### Process-Related Investigations

| Process | Number of Investigations | Critical | Major | Minor | Recurring Issues |
|---------|--------------------------|---------|-------|-------|------------------|
| [Process 1] | [Total] | [Number] | [Number] | [Number] | [Yes/No] |
| [Process 2] | [Total] | [Number] | [Number] | [Number] | [Yes/No] |

#### Process Performance Analysis

[Provide analysis of process stability, capability, trends, and improvement opportunities. Focus on critical processes showing instability or declining performance.]

### Product Quality Review

#### Annual Product Review (APR) Status

| Product | APR Due Date | Status | Critical Findings | Action Items |
|---------|--------------|--------|-------------------|--------------|
| [Product 1] | [Date] | [Complete/In Progress/Overdue] | [Yes/No] | [Number] |
| [Product 2] | [Date] | [Complete/In Progress/Overdue] | [Yes/No] | [Number] |

#### Product Quality Indicators

| Product | Batch Conformance | Stability Results | Complaint Rate | Field Alert Reports |
|---------|-------------------|-------------------|----------------|---------------------|
| [Product 1] | [Percentage]% | [Satisfactory/Unsatisfactory] | [Rate] | [Number] |
| [Product 2] | [Percentage]% | [Satisfactory/Unsatisfactory] | [Rate] | [Number] |

#### Product-Specific Issues

| Product | Issue Description | Risk Level | Mitigation Status | CAPA Reference |
|---------|-------------------|------------|-------------------|----------------|
| [Product 1] | [Description] | [High/Medium/Low] | [Status] | [Reference] |
| [Product 2] | [Description] | [High/Medium/Low] | [Status] | [Reference] |

#### Product Quality Analysis

[Provide analysis of product quality trends, critical APR findings, stability concerns, and complaint patterns. Include product lifecycle considerations and continuous improvement opportunities.]

### Inspection and Audit Findings

#### Regulatory Inspections

| Regulatory Agency | Inspection Date | Type | Classification | Critical Findings | Major Findings | Minor Findings |
|-------------------|-----------------|------|----------------|-------------------|----------------|----------------|
| [Agency] | [Date] | [GMP/PAI/Other] | [Classification] | [Number] | [Number] | [Number] |

#### External Audits

| Auditing Organization | Audit Date | Scope | Critical Findings | Major Findings | Minor Findings |
|-----------------------|------------|-------|-------------------|----------------|----------------|
| [Organization] | [Date] | [Scope] | [Number] | [Number] | [Number] |

#### Internal Audits

| Area Audited | Audit Date | Critical Findings | Major Findings | Minor Findings | CAPA Status |
|--------------|------------|-------------------|----------------|----------------|-------------|
| [Area] | [Date] | [Number] | [Number] | [Number] | [Status] |

#### Top Audit Findings by Category

| Finding Category | Number of Occurrences | Risk Level | Systemic Issue? | Trending |
|------------------|------------------------|------------|-----------------|----------|
| [Category 1] | [Number] | [High/Medium/Low] | [Yes/No] | [↑/↓/→] |
| [Category 2] | [Number] | [High/Medium/Low] | [Yes/No] | [↑/↓/→] |

#### Inspection and Audit Analysis

[Provide analysis of inspection results, recurrent themes, effectiveness of CAPA responses, and preparation strategy for upcoming inspections. Include comparison to industry trends if available.]

### CAPA Status and Effectiveness

#### CAPA Metrics

| CAPA Metric | Target | Current Period | Previous Period | Trend | Status |
|-------------|--------|----------------|----------------|-------|--------|
| Open CAPAs | [Target] | [Number] | [Number] | [↑/↓/→] | [Color] |
| Overdue CAPAs | ≤5% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Average Age of Open CAPAs | ≤45 days | [Value] days | [Value] days | [↑/↓/→] | [Color] |
| CAPA Effectiveness Success Rate | ≥90% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Repeat CAPAs (similar root cause) | ≤5% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |

#### CAPA Source Analysis

| CAPA Source | Number | Percentage | Critical | Major | Minor |
|-------------|--------|------------|---------|-------|-------|
| Deviations | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Complaints | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Audit Findings | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Lab Investigations | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Process Monitoring | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Other | [Number] | [Percentage]% | [Number] | [Number] | [Number] |

#### Critical CAPAs Status

| CAPA ID | Issue Description | Risk Level | Due Date | Status | Effectiveness Check Status |
|---------|-------------------|------------|----------|--------|----------------------------|
| [ID] | [Description] | [High/Medium/Low] | [Date] | [Status] | [Status] |

#### CAPA Effectiveness Analysis

[Provide analysis of CAPA system effectiveness, root cause determination adequacy, timeliness of implementations, recurring issues, and improvement opportunities for the CAPA process.]

### Change Control Review

#### Change Control Metrics

| Change Control Metric | Target | Current Period | Previous Period | Trend | Status |
|-----------------------|--------|----------------|----------------|-------|--------|
| Open Changes | [Target] | [Number] | [Number] | [↑/↓/→] | [Color] |
| Changes Implemented On-Time | ≥90% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Average Change Cycle Time | ≤60 days | [Value] days | [Value] days | [↑/↓/→] | [Color] |
| Post-Implementation Review Success Rate | ≥95% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Emergency Changes | ≤5% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |

#### Change Category Analysis

| Change Category | Number | Percentage | Critical | Major | Minor |
|-----------------|--------|------------|---------|-------|-------|
| Equipment/Facility | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Process | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Documentation | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Computer Systems | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Materials/Components | [Number] | [Percentage]% | [Number] | [Number] | [Number] |
| Other | [Number] | [Percentage]% | [Number] | [Number] | [Number] |

#### Significant Changes Review

| Change ID | Description | Risk Level | Implementation Date | Post-Implementation Review Status | Issues Identified |
|-----------|-------------|------------|---------------------|-----------------------------------|-------------------|
| [ID] | [Description] | [High/Medium/Low] | [Date] | [Status] | [Yes/No] |

#### Change Control Analysis

[Provide analysis of change control system effectiveness, change implementation quality, risk assessment adequacy, and impact on quality system and product quality.]

### Supplier Quality Assessment

#### Supplier Qualification Status

| Supplier Type | Total | Approved | Conditionally Approved | Disapproved | Pending Qualification |
|---------------|-------|----------|------------------------|-------------|----------------------|
| Critical (Tier 1) | [Number] | [Number] | [Number] | [Number] | [Number] |
| Major (Tier 2) | [Number] | [Number] | [Number] | [Number] | [Number] |
| Minor (Tier 3) | [Number] | [Number] | [Number] | [Number] | [Number] |

#### Supplier Performance Metrics

| Supplier Performance Metric | Target | Current Period | Previous Period | Trend | Status |
|-----------------------------|--------|----------------|----------------|-------|--------|
| On-Time Delivery Rate | ≥95% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Material Acceptance Rate | ≥98% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Supplier Deviation Rate | ≤2% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Supplier Audit Program Completion | 100% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Supplier CAPA Response Time | ≤30 days | [Value] days | [Value] days | [↑/↓/→] | [Color] |

#### Critical Supplier Review

| Supplier | Materials/Services | Risk Level | Last Audit | Key Issues | Performance Rating |
|----------|-------------------|------------|------------|------------|-------------------|
| [Supplier 1] | [Description] | [High/Medium/Low] | [Date] | [Description] | [Rating] |
| [Supplier 2] | [Description] | [High/Medium/Low] | [Date] | [Description] | [Rating] |

#### Supplier Quality Analysis

[Provide analysis of supplier quality program effectiveness, critical supplier performance trends, supply chain risks, and improvement initiatives.]

### Training Program Effectiveness

#### Training Compliance Metrics

| Training Metric | Target | Current Period | Previous Period | Trend | Status |
|-----------------|--------|----------------|----------------|-------|--------|
| Overall Training Compliance | ≥98% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| GMP Training Compliance | 100% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| SOP Training Compliance | ≥98% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| On-Time Training Completion | ≥95% | [Percentage]% | [Percentage]% | [↑/↓/→] | [Color] |
| Training-Related Deviations | ≤5 | [Number] | [Number] | [↑/↓/→] | [Color] |

#### Training Effectiveness Assessment

| Training Area | Knowledge Assessment | Application Assessment | Quality Impact | Issues Identified |
|---------------|----------------------|------------------------|---------------|-------------------|
| GMP Fundamentals | [Score] | [Score] | [High/Medium/Low] | [Yes/No] |
| Aseptic Processing | [Score] | [Score] | [High/Medium/Low] | [Yes/No] |
| Documentation Practices | [Score] | [Score] | [High/Medium/Low] | [Yes/No] |
| [Other Areas] | [Score] | [Score] | [High/Medium/Low] | [Yes/No] |

#### Department Training Analysis

| Department | Compliance Rate | Effectiveness Score | Key Gaps | Action Plan |
|------------|----------------|---------------------|----------|-------------|
| [Department 1] | [Percentage]% | [Score] | [Description] | [Yes/No] |
| [Department 2] | [Percentage]% | [Score] | [Description] | [Yes/No] |

#### Training Program Analysis

[Provide analysis of training program effectiveness, correlation between training gaps and quality issues, and recommendations for training program improvements.]

## Risk Assessment and Mitigation

### Quality Risk Assessment Status

| Risk Assessment Type | Completion Status | Last Review Date | Next Review Due | Critical Risks Identified |
|----------------------|-------------------|------------------|----------------|---------------------------|
| Product Quality | [Complete/In Progress] | [Date] | [Date] | [Yes/No] |
| Process Validation | [Complete/In Progress] | [Date] | [Date] | [Yes/No] |
| Supplier Management | [Complete/In Progress] | [Date] | [Date] | [Yes/No] |
| Computer System Validation | [Complete/In Progress] | [Date] | [Date] | [Yes/No] |
| Data Integrity | [Complete/In Progress] | [Date] | [Date] | [Yes/No] |

### Top Quality Risks

| Risk Description | Risk Level | Probability | Impact | Detection | RPN | Mitigation Status |
|------------------|------------|------------|--------|-----------|-----|-------------------|
| [Description] | [High/Medium/Low] | [Rating] | [Rating] | [Rating] | [Value] | [Status] |
| [Description] | [High/Medium/Low] | [Rating] | [Rating] | [Rating] | [Value] | [Status] |
| [Description] | [High/Medium/Low] | [Rating] | [Rating] | [Rating] | [Value] | [Status] |

### Risk Mitigation Effectiveness

| Risk Control Measure | Implementation Status | Effectiveness Verification | Residual Risk Level | Additional Controls Needed |
|----------------------|----------------------|----------------------------|---------------------|---------------------------|
| [Description] | [Status] | [Complete/Pending] | [High/Medium/Low] | [Yes/No] |
| [Description] | [Status] | [Complete/Pending] | [High/Medium/Low] | [Yes/No] |
| [Description] | [Status] | [Complete/Pending] | [High/Medium/Low] | [Yes/No] |

### Emerging Risks

| Emerging Risk | Source | Potential Impact | Probability | Current Assessment | Monitoring Plan |
|---------------|--------|------------------|------------|-------------------|----------------|
| [Description] | [Source] | [Description] | [Rating] | [Status] | [Description] |
| [Description] | [Source] | [Description] | [Rating] | [Status] | [Description] |

### Risk Assessment Analysis

[Provide analysis of risk management process effectiveness, status of risk mitigation activities, emerging risk factors, and recommendations for risk management improvement.]

## Resource Requirements Review

### Quality Personnel Resources

| Department | Current Headcount | Approved Headcount | Gap | Recruitment Status | Impact on Quality |
|------------|-------------------|-------------------|-----|-------------------|-------------------|
| Quality Assurance | [Number] | [Number] | [Number] | [Status] | [High/Medium/Low] |
| Quality Control | [Number] | [Number] | [Number] | [Status] | [High/Medium/Low] |
| Validation | [Number] | [Number] | [Number] | [Status] | [High/Medium/Low] |
| Regulatory Affairs | [Number] | [Number] | [Number] | [Status] | [High/Medium/Low] |

### Technical Resources

| Resource Category | Current Status | Gap Assessment | Action Plan | Timeframe |
|-------------------|----------------|----------------|------------|-----------|
| Laboratory Equipment | [Status] | [Description] | [Description] | [Timeframe] |
| Manufacturing Equipment | [Status] | [Description] | [Description] | [Timeframe] |
| Computer Systems | [Status] | [Description] | [Description] | [Timeframe] |
| Facilities | [Status] | [Description] | [Description] | [Timeframe] |

### Budget Status

| Budget Category | Annual Budget | YTD Spent | % Utilized | Forecast | Variance |
|-----------------|---------------|-----------|------------|----------|----------|
| Quality Personnel | [Amount] | [Amount] | [Percentage]% | [Amount] | [Amount] |
| Training | [Amount] | [Amount] | [Percentage]% | [Amount] | [Amount] |
| External Testing | [Amount] | [Amount] | [Percentage]% | [Amount] | [Amount] |
| Consulting Services | [Amount] | [Amount] | [Percentage]% | [Amount] | [Amount] |
| Technology/Systems | [Amount] | [Amount] | [Percentage]% | [Amount] | [Amount] |
| Capital Projects | [Amount] | [Amount] | [Percentage]% | [Amount] | [Amount] |

### Resource Analysis

[Provide analysis of resource adequacy, impact of resource constraints on quality, prioritization of resource needs, and recommendations for resource optimization.]

## Improvement Initiatives

### Current Quality Improvement Projects

| Project Name | Description | Start Date | Target Completion | Status | % Complete | Business Impact |
|--------------|-------------|------------|-------------------|--------|------------|----------------|
| [Project Name] | [Description] | [Date] | [Date] | [Status] | [Percentage]% | [High/Medium/Low] |
| [Project Name] | [Description] | [Date] | [Date] | [Status] | [Percentage]% | [High/Medium/Low] |
| [Project Name] | [Description] | [Date] | [Date] | [Status] | [Percentage]% | [High/Medium/Low] |

### Completed Improvement Initiatives

| Initiative | Completion Date | Key Results | Benefits Realized | Lessons Learned |
|------------|-----------------|------------|-------------------|----------------|
| [Initiative] | [Date] | [Description] | [Description] | [Description] |
| [Initiative] | [Date] | [Description] | [Description] | [Description] |

### Proposed Improvement Opportunities

| Improvement Area | Description | Expected Benefit | Required Resources | Priority | ROI Assessment |
|------------------|-------------|------------------|-------------------|----------|---------------|
| [Area] | [Description] | [Description] | [Description] | [High/Medium/Low] | [High/Medium/Low] |
| [Area] | [Description] | [Description] | [Description] | [High/Medium/Low] | [High/Medium/Low] |
| [Area] | [Description] | [Description] | [Description] | [High/Medium/Low] | [High/Medium/Low] |

### Continuous Improvement Analysis

[Provide analysis of improvement initiative effectiveness, prioritization methodology, resource allocation strategy, and recommendations for continuous improvement program enhancement.]

## Review Meeting Minutes Template

### Meeting Details

| Meeting Type | [Regular QMR/Annual Management Review/Special Review] |
|--------------|-----------------------------------------------------|
| Date | [Meeting Date] |
| Time | [Start Time] - [End Time] |
| Location | [Physical Location/Virtual Platform] |
| Chair | [Name and Role] |
| Minute Taker | [Name and Role] |

### Attendees

| Name | Role | Present | Absent |
|------|------|---------|--------|
| [Name] | [Role] | [✓/✗] | [✓/✗] |
| [Name] | [Role] | [✓/✗] | [✓/✗] |
| [Name] | [Role] | [✓/✗] | [✓/✗] |

### Agenda

1. Review of previous meeting minutes and action items
2. Quality metrics review
3. Significant quality events and CAPA status
4. Audit and inspection findings
5. Product quality review
6. Process performance review
7. Supplier quality status
8. Risk management updates
9. Resource adequacy assessment
10. Continuous improvement initiatives
11. New business
12. Action items and assignments

### Discussion Summary

| Agenda Item | Discussion Points | Decisions Made |
|-------------|-------------------|----------------|
| [Item 1] | [Summary of discussion] | [Decisions] |
| [Item 2] | [Summary of discussion] | [Decisions] |
| [Item 3] | [Summary of discussion] | [Decisions] |

### Quality System Assessment

| System Component | Status | Trend | Key Issues | Strengths |
|------------------|--------|-------|------------|-----------|
| Quality Control | [Status] | [↑/↓/→] | [Issues] | [Strengths] |
| Document Management | [Status] | [↑/↓/→] | [Issues] | [Strengths] |
| Training | [Status] | [↑/↓/→] | [Issues] | [Strengths] |
| CAPA | [Status] | [↑/↓/→] | [Issues] | [Strengths] |
| Change Control | [Status] | [↑/↓/→] | [Issues] | [Strengths] |
| Other Components | [Status] | [↑/↓/→] | [Issues] | [Strengths] |

### Meeting Minutes Template Example:

**Quality Management Review - Q2 2025**

**Date:** July 15, 2025  
**Time:** 09:00 - 12:30  
**Location:** Board Room and Teams Meeting  
**Chair:** J. Smith, Head of Quality  
**Minute Taker:** A. Johnson, Quality Systems Specialist

**Attendees:**
- J. Smith, Head of Quality
- R. Williams, Site Director
- M. Brown, Head of Manufacturing
- S. Davis, Head of QC
- T. Wilson, Regulatory Affairs
- L. Johnson, Validation Manager
- K. Martinez, Supply Chain Manager

**Key Discussion Points:**

1. **CAPA System Performance**
   - CAPA closure rate improved from 85% to 92% this quarter
   - Effectiveness check failure rate decreased from 12% to 8%
   - Recurring issue with documentation errors in Area B identified
   - Decision: Implement targeted documentation training for Area B personnel

2. **Audit Findings**
   - Successful FDA inspection with zero 483 observations
   - Internal audit program on track with 95% completion rate
   - Common findings related to equipment maintenance documentation
   - Decision: Conduct focused review of equipment maintenance procedures

3. **Resource Requirements**
   - QC department currently at 85% staffing with active recruitment
   - Impact on testing turnaround time evident but within acceptable limits
   - Budget for laboratory equipment upgrades approved
   - Decision: Expedite QC analyst hiring through external recruitment agency

## Action Items and Follow-up

### Action Item Tracking

| Action Item | Description | Priority | Responsible | Due Date | Status | Progress Update |
|-------------|-------------|----------|------------|----------|--------|----------------|
| [Item ID] | [Description] | [High/Medium/Low] | [Name] | [Date] | [Open/In Progress/Completed] | [Update] |
| [Item ID] | [Description] | [High/Medium/Low] | [Name] | [Date] | [Open/In Progress/Completed] | [Update] |
| [Item ID] | [Description] | [High/Medium/Low] | [Name] | [Date] | [Open/In Progress/Completed] | [Update] |

### Escalation Process

| Priority Level | Review Frequency | Escalation Trigger | Escalation Path |
|----------------|------------------|-------------------|----------------|
| High | Weekly | No progress after 2 weeks | Department Head → Quality Head → Site Head |
| Medium | Bi-weekly | No progress after 3 weeks | Department Head → Quality Head |
| Low | Monthly | No progress after 6 weeks | Department Head |

### Previous Action Items Status

| Action Item | From Meeting | Responsible | Original Due Date | Status | Closure Date | Effectiveness |
|-------------|--------------|------------|-------------------|--------|--------------|--------------|
| [Item ID] | [Date] | [Name] | [Date] | [Status] | [Date] | [Effective/Partially Effective/Not Effective] |
| [Item ID] | [Date] | [Name] | [Date] | [Status] | [Date] | [Effective/Partially Effective/Not Effective] |
| [Item ID] | [Date] | [Name] | [Date] | [Status] | [Date] | [Effective/Partially Effective/Not Effective] |

### Follow-up Verification Plan

[Outline the process for verifying the completion and effectiveness of action items, including responsible parties, verification methodology, and documentation requirements.]

## Quality Metrics Dashboard Integration

### Dashboard Implementation

| Dashboard Element | Data Source | Update Frequency | Owner | User Access |
|-------------------|-------------|------------------|-------|------------|
| Executive Summary | Quality KPIs | Weekly | Quality Systems | Senior Management |
| Manufacturing Metrics | MES/EBR System | Daily | Manufacturing | Production/Quality |
| Lab Testing Metrics | LIMS | Daily | QC | Laboratory/Quality |
| CAPA Metrics | Quality Management System | Weekly | Quality Assurance | All Quality Staff |
| Supplier Metrics | ERP/Supplier Management System | Monthly | Supply Chain | Procurement/Quality |

### Dashboard Visualization Guidelines

**Design Principles:**
- Use consistent color scheme (Green/Yellow/Red for status indicators)
- Implement trend indicators (↑/↓/→) for performance over time
- Include both tabular data and graphical representations
- Establish standard thresholds for all metrics
- Provide drill-down capabilities for root cause analysis

**Key Visualization Components:**
1. Trend Charts - Display performance over 12-month period
2. Control Charts - Show process stability and capability
3. Pareto Charts - Identify most significant quality issues
4. Heat Maps - Highlight problem areas across products/processes
5. Scorecard Summary - Present high-level status for executive review

### Data Collection and Integration

| Data Type | Collection Method | System Integration | Data Quality Checks | Frequency |
|-----------|-------------------|-------------------|---------------------|-----------|
| Manufacturing Data | Automated from MES | API Connection | Validation Rules | Real-time |
| Laboratory Data | Automated from LIMS | API Connection | Validation Rules | Daily |
| Deviation Data | Manual Entry/QMS | Database Query | Supervisory Review | Weekly |
| Audit Findings | Manual Entry | Database Query | QA Review | Per Audit |
| Customer Complaints | CRM System | API Connection | Investigation Verification | Weekly |

### Industry-Specific KPI Recommendations

**Pharmaceutical Manufacturing:**
- Process Capability Indices (Cpk)
- Particulate Matter Control
- Sterility Assurance Metrics
- Yield Consistency
- Cross-Contamination Control Effectiveness

**Biologics:**
- Cell Culture Performance
- Protein Yield
- Purification Efficiency
- Host Cell Protein Clearance
- Endotoxin Level Control

**Medical Devices:**
- Component Acceptance Rates
- Sterilization Validation Metrics
- Package Integrity Testing
- Device Functional Testing Results
- Material Compatibility Verification

### Dashboard Review Process

**Review Frequency:**
- Daily Operational Review: Process-level metrics
- Weekly Management Review: Department-level metrics
- Monthly Executive Review: Site-level summary metrics
- Quarterly Quality Management Review: Comprehensive metrics package

**Integration with Quality Management Review:**
- Pre-meeting distribution of dashboard summary (3 days prior)
- Focus on exceptions and negative trends during review
- Record of dashboard metrics included in meeting minutes
- Action items linked to specific metrics requiring improvement

### Example Dashboard Metrics

**Executive Summary Dashboard:**

| Metric | Current | Target | Status | Trend | 12-Month Chart |
|--------|---------|--------|--------|-------|----------------|
| Overall Quality Score | 94.2% | ≥95% | Yellow | ↑ | [Sparkline] |
| CAPA Effectiveness | 92% | ≥90% | Green | ↑ | [Sparkline] |
| Batch Right First Time | 93.5% | ≥95% | Yellow | ↑ | [Sparkline] |
| Regulatory Compliance | 98.5% | ≥98% | Green | → | [Sparkline] |
| Complaint Rate (ppm) | 3.2 | ≤5.0 | Green | ↓ | [Sparkline] |

## Appendices

### Appendix A: Regulatory References

**FDA Guidance Documents:**
- FDA Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations
- FDA Guidance for Industry: Q10 Pharmaceutical Quality System
- FDA Guidance for Industry: Q9 Quality Risk Management
- FDA Guidance for Industry: Process Validation
- 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals

**EU Regulatory References:**
- EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use (EudraLex Volume 4)
- EU GMP Chapter 1 - Pharmaceutical Quality System
- EU GMP Annex 15 - Qualification and Validation
- EU GMP Annex 16 - Certification by a Qualified Person and Batch Release

**ICH Guidelines:**
- ICH Q8(R2) Pharmaceutical Development
- ICH Q9 Quality Risk Management
- ICH Q10 Pharmaceutical Quality System
- ICH Q11 Development and Manufacture of Drug Substances
- ICH Q12 Lifecycle Management

### Appendix B: Review Preparation Checklist

**Four Weeks Before Review:**
- [ ] Schedule meeting and notify participants
- [ ] Distribute data collection templates to functional areas
- [ ] Review previous management review minutes and action items
- [ ] Update quality metrics dashboard

**Two Weeks Before Review:**
- [ ] Collect and compile data from all functional areas
- [ ] Analyze trends and identify significant issues
- [ ] Prepare preliminary presentation materials
- [ ] Review draft with key stakeholders

**One Week Before Review:**
- [ ] Finalize presentation materials
- [ ] Distribute agenda and pre-read materials
- [ ] Confirm participant availability
- [ ] Prepare meeting logistics

**Post-Review Activities:**
- [ ] Distribute meeting minutes within 5 business days
- [ ] Enter action items into tracking system
- [ ] Schedule follow-up reviews for critical items
- [ ] Communicate key decisions to organization

### Appendix C: Quality Risk Assessment Methodology

**Risk Assessment Tools:**
- Failure Mode and Effects Analysis (FMEA)
- Hazard Analysis and Critical Control Points (HACCP)
- Hazard Operability Analysis (HAZOP)
- Preliminary Hazard Analysis (PHA)
- Risk Ranking and Filtering
- Fault Tree Analysis

**Risk Assessment Process:**
1. Risk Identification
2. Risk Analysis
3. Risk Evaluation
4. Risk Control
5. Risk Communication
6. Risk Review

**Risk Quantification:**
- Probability (P): 1-5 scale (1=Rare, 5=Almost Certain)
- Impact (I): 1-5 scale (1=Negligible, 5=Catastrophic)
- Detection (D): 1-5 scale (1=Certain Detection, 5=Cannot Detect)
- Risk Priority Number (RPN) = P × I × D

### Appendix D: Change History

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | 2025-06-20 | [Author Name] | Initial template creation |

---

*Note: This template is designed to be customized based on specific organizational needs while ensuring compliance with regulatory requirements. It provides a structured approach to performing quality management reviews in the pharmaceutical and healthcare industries.*